The important lessons lurking in the history of meningococcal epidemiology

References

• Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388. doi: 10.1056/NEJM200105033441807
   PubMed Web of Science ®Google Scholar
• Olbrich KJ, Muller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–438. doi: 10.1007/s40121-018-0213-2
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningitis [Internet]. [cited 2023 Feb 14]. Available from: https://www.who.int/news-room/fact-sheets/detail/meningitis
   Google Scholar
• Mbaeyi S, Duffy J, McNamara LA. Meningococcal disease. In: Hall E, Wodi A, and Hamborsky J, et al., editors. Epidemiology and prevention of vaccine-preventable diseases. 14th ed. Washington, DC: Public Health Foundation; 2021. p. 207–224. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf
   Google Scholar
• Gyamfi-Brobbey G, Clark SA, Campbell H, et al. An analysis of Neisseria meningitidis strains causing meningococcal septic arthritis in England and Wales: 2010–2020. J Infect. 2022;85(4):390–396. doi: 10.1016/j.jinf.2022.07.019
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403. doi: 10.1016/S0140-6736(06)67932-4
   PubMed Web of Science ®Google Scholar
• Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–2782. doi: 10.1016/j.vaccine.2019.04.020
   PubMed Web of Science ®Google Scholar
• Deghmane AE, Taha S, Taha MK. Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review. Infect Dis. 2022;54(1):1–7. doi: 10.1080/23744235.2021.1971289
   PubMed Web of Science ®Google Scholar
• Pardo de Santayana C, Tin Tin Htar M, Findlow J, et al. Epidemiology of invasive meningococcal disease worldwide from 2010–2019: a literature review. Epidemiol Infect. 2023;151:e57. doi: 10.1017/S0950268823000328
   PubMed Web of Science ®Google Scholar
• World Health Organization. Defeating meningitis by 2030: a global road map [Internet]. [cited 2024 Feb 7]. Available from: https://iris.who.int/bitstream/handle/10665/342010/9789240026407-eng.pdf?sequence=1
   Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Bio. 2012;799:1–20. doi: 10.1007/978-1-61779-346-2_1
   PubMedGoogle Scholar
• Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–861. doi: 10.1016/S1473-3099(10)70251-6
   PubMed Web of Science ®Google Scholar
• Clark SA, Borrow R. Herd protection against meningococcal disease through vaccination. Microorganisms. 2020;8(11):1675. doi: 10.3390/microorganisms8111675
   PubMed Web of Science ®Google Scholar
• Balmer P, Burman C, Serra L, et al. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118–1130. doi: 10.1080/21645515.2018.1454570
   PubMed Web of Science ®Google Scholar
• Bartley SN, Mowlaboccus S, Mullally CA, et al. Acquisition of the capsule locus by horizontal gene transfer in Neisseria meningitidis is often accompanied by the loss of UDP-GalNAc synthesis. Sci Rep. 2017;7(1):44442. doi: 10.1038/srep44442
   PubMedGoogle Scholar
• Clemence MEA, Harrison OB, Maiden MCJ. Neisseria meningitidis has acquired sequences within the capsule locus by horizontal genetic transfer. Wellcome Open Res. 2019;4:99. doi: 10.12688/wellcomeopenres.15333.2
   PubMedGoogle Scholar
• Cartwright K. Introduction and historical aspects. In: Cartwright K, editor. Meningococcal disease. Chichester, NY: J. Wiley & Sons; 1995. p. 1–20.
   Google Scholar
• da Silva RAG, Karlyshev AV, Oldfield NJ, et al. Variant signal peptides of vaccine antigen, FHbp, impair processing affecting surface localization and antibody-mediated killing in most meningococcal isolates. Front Microbiol. 2019;10:2847. doi: 10.3389/fmicb.2019.02847
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–573. doi: 10.3201/eid1904.111799
   PubMed Web of Science ®Google Scholar
• Coureuil M, Join-Lambert O, Lécuyer H, et al. Mechanism of meningeal invasion by Neisseria meningitidis. Virulence. 2012;3(2):164–172. doi: 10.4161/viru.18639
   PubMed Web of Science ®Google Scholar
• Tzeng YL, Stephens DS. A narrative review of the W, X, Y, E, and NG of meningococcal disease: emerging capsular groups, pathotypes, and global control. Microorganisms. 2021;9:519. doi: 10.3390/microorganisms9030519
   PubMed Web of Science ®Google Scholar
• Peak IR, Chen A, Jen FE, et al. Neisseria meningitidis lacking the major porins PorA and PorB is viable and modulates apoptosis and the oxidative burst of neutrophils. J Proteome Res. 2016;15(8):2356–2365. doi: 10.1021/acs.jproteome.5b00938
   PubMed Web of Science ®Google Scholar
• Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child. 2003;88(7):601–607. doi: 10.1136/adc.88.7.601
   PubMed Web of Science ®Google Scholar
• Parrow NL, Fleming RE, Minnick MF, et al. Sequestration and scavenging of iron in infection. Infect Immun. 2013;81(10):3503–3514. doi: 10.1128/IAI.00602-13
   PubMed Web of Science ®Google Scholar
• Shortt GA, Ren X, Otto BM, et al. The Neisseria meningitidis iron acquisition protein HpuA moonlights as an adhesin and inhibits host cell migration. bioRxiv. Preprint posted online Feb 25, 2023. doi: 10.1101/2022.02.25.481912
   Google Scholar
• Jordan PW, Saunders NJ, Fox D. Host iron binding proteins acting as niche indicators for Neisseria meningitidis. PLoS One. 2009;4(4):e5198. doi: 10.1371/journal.pone.0005198
   PubMed Web of Science ®Google Scholar
• Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun. 2009;77(2):764–769. doi: 10.1128/IAI.01191-08
   PubMed Web of Science ®Google Scholar
• Hill DJ, Griffiths NJ, Borodina E, et al. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond). 2010;118(9):547–564. doi: 10.1042/CS20090513
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010;6(7):e1001027. doi: 10.1371/journal.ppat.1001027
   PubMed Web of Science ®Google Scholar
• Clark SA, Lekshmi A, Lucidarme J, et al. Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution. J Infect. 2016;73(1):63–70. doi: 10.1016/j.jinf.2016.03.012
   PubMed Web of Science ®Google Scholar
• Findlow J, Bayliss CD, Beernink PT, et al. Broad vaccine protection against Neisseria meningitidis using factor H binding protein. Vaccine. 2020;38(49):7716–7727. doi: 10.1016/j.vaccine.2020.08.031
   PubMed Web of Science ®Google Scholar
• Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.Org website and their applications. Wellcome Open Res. 2018;3:124. doi: 10.12688/wellcomeopenres.14826.1
   PubMedGoogle Scholar
• McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9(2):e00036–00018. doi: 10.1128/mBio.00036-18
   PubMed Web of Science ®Google Scholar
• Nguyen N, Ashong D. Neisseria Meningitidis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022. https://pubmed.ncbi.nlm.nih.gov/31751039/
   Google Scholar
• Diggle MA, Clarke SC. Molecular methods for the detection and characterization of Neisseria meningitidis. Expert Rev Mol Diagn. 2006;6(1):79–87. doi: 10.1586/14737159.6.1.79
   PubMed Web of Science ®Google Scholar
• Castillo D, Harcourt B, Hatcher C, et al. Primary culture and presumptive identification of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. In: Mayer L, editor. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae: WHO Manual. 2nd ed. Geneva, Switzerland: WHO Press, World Health Organization; 2011. p. 32–56. https://iris.who.int/bitstream/handle/10665/70765/WHO_IVB_11.09_eng.pdf?sequence=1
   Google Scholar
• Shenoy B, Biradar S. Latex Agglutination Test (LAT)–for rapid diagnosis of acute bacterial meningitis. Pediatr Infect Dis. 2014;6(4):150–152. doi: 10.1016/j.pid.2014.10.004
   Google Scholar
• Castillo D, Harcourt B, Hatcher C, et al. Identification and characterization of Neisseria meningitidis. In: Mayer L, editor. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae: WHO Manual. 2nd ed. Geneva, Switzerland: WHO Press, World Health Organization; 2011. p. 57–72. https://iris.who.int/bitstream/handle/10665/70765/WHO_IVB_11.09_eng.pdf?sequence=1
   Google Scholar
• Rosenqvist E, Wedege E, Høiby EA, et al. Serogroup determination of Neisseria meningitidis by whole-cell ELISA, dot-blotting and agglutination. APMIS. 1990;98(1–6):501–506. doi: 10.1111/j.1699-0463.1990.tb01063.x
   PubMed Web of Science ®Google Scholar
• Tsai CM, Civin CI. Eight lipooligosaccharides of Neisseria meningitidis react with a monoclonal antibody which binds lacto-N-neotetraose (Galβ1-4GlcNAcβ1-3Galβ1-4Glc). Infect Immun. 1991;59(10):3604–3609. doi: 10.1128/iai.59.10.3604-3609.1991
   PubMed Web of Science ®Google Scholar
• Mistretta N, Seguin D, Thiébaud J, et al. Genetic and structural characterization of L11 lipooligosaccharide from Neisseria meningitidis serogroup A strains. J Biol Chem. 2010;285(26):19874–19883. doi: 10.1074/jbc.M110.100636
   PubMed Web of Science ®Google Scholar
• Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31(1):89–96. doi: 10.1111/j.1574-6976.2006.00057.x
   PubMed Web of Science ®Google Scholar
• Caugant DA, Bovre K, Gaustad P, et al. Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. J Gen Microbiol. 1986;132(3):641–652. doi: 10.1099/00221287-132-3-641
   PubMedGoogle Scholar
• Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA. 1998;95(6):3140–3145. doi: 10.1073/pnas.95.6.3140
   PubMed Web of Science ®Google Scholar
• Besser J, Carleton HA, Gerner-Smidt P, et al. Next-generation sequencing technologies and their application to the study and control of bacterial infections. Clin Microbiol Infect. 2018;24(4):335–341. doi: 10.1016/j.cmi.2017.10.013
   PubMed Web of Science ®Google Scholar
• Urwin R, Maiden MC. Multi-locus sequence typing: a tool for global epidemiology. Trends Microbiol. 2003;11(10):479–487. doi: 10.1016/j.tim.2003.08.006
   PubMed Web of Science ®Google Scholar
• Jolley KA, Maiden MC. AgdbNet – antigen sequence database software for bacterial typing. BMC Bioinf. 2006;7(1):314. doi: 10.1186/1471-2105-7-314
   PubMedGoogle Scholar
• Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29–30):4739–4744. doi: 10.1016/j.vaccine.2011.04.092
   PubMed Web of Science ®Google Scholar
• Rodgers E, Bentley SD, Borrow R, et al. The global meningitis genome partnership. J Infect. 2020;81(4):510–520. doi: 10.1016/j.jinf.2020.06.064
   PubMed Web of Science ®Google Scholar
• Clark SA, Lucidarme J, Newbold LS, et al. Genotypic analysis of meningococcal factor H-binding protein from non-culture clinical specimens. PLoS One. 2014;9(2):e89921. doi: 10.1371/journal.pone.0089921
   PubMed Web of Science ®Google Scholar
• Itsko M, Retchless AC, Joseph SJ, et al. Full molecular typing of Neisseria meningitidis directly from clinical specimens for outbreak investigation. J Clin Microbiol. 2020;58(12):e01780–01720. doi: 10.1128/JCM.01780-20
   PubMed Web of Science ®Google Scholar
• Clark SA, Doyle R, Lucidarme J, et al. Targeted DNA enrichment and whole genome sequencing of Neisseria meningitidis directly from clinical specimens. Int J Med Microbiol. 2018;308(2):256–262. doi: 10.1016/j.ijmm.2017.11.004
   PubMed Web of Science ®Google Scholar
• Alderson MR, Arkwright PD, Bai X, et al. Surveillance and control of meningococcal disease in the COVID-19 era: a Global Meningococcal Initiative review. J Infect. 2022;84(3):289–296. doi: 10.1016/j.jinf.2021.11.016
   PubMed Web of Science ®Google Scholar
• Aye AMM, Bai X, Borrow R, et al. Meningococcal disease surveillance in the Asia–Pacific region (2020): the Global Meningococcal Initiative. J Infect. 2020;81(5):698–711. doi: 10.1016/j.jinf.2020.07.025
   PubMed Web of Science ®Google Scholar
• Potts CC, Retchless AC, McNamara LA, et al. Acquisition of ciprofloxacin resistance among an expanding clade of β-lactamase–positive, serogroup Y Neisseria meningitidis in the United States. Clinical Infectious Diseases. 2021;73(7):1185–1193. doi: 10.1093/cid/ciab358
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–1520. doi: 10.1056/NEJMra0906357
   PubMed Web of Science ®Google Scholar
• Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30:B10–17. doi: 10.1016/j.vaccine.2011.12.060
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Stephens DS, et al. Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. Expert Rev Vaccines. 2022;21(6):753–769. doi: 10.1080/14760584.2022.2064850
   PubMed Web of Science ®Google Scholar
• Luo W, Arkwright PD, Borrow R. Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine. Expert Rev Vaccines. 2020;19(8):745–754. doi: 10.1080/14760584.2020.1800460
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20:S58–S67. doi: 10.1016/S0264-410X(01)00299-7
   PubMed Web of Science ®Google Scholar
• Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8(10):1521. doi: 10.3390/microorganisms8101521
   PubMed Web of Science ®Google Scholar
• Carr JP, MacLennan JM, Plested E, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649.e1–1649.e8. doi: 10.1016/j.cmi.2022.07.004
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743. doi: 10.1086/527401
   PubMed Web of Science ®Google Scholar
• Mbaeyi S, Sampo E, Dinanibe K, et al. Meningococcal carriage 7 years after introduction of a serogroup a meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys. Lancet Infect Dis. 2020;20(12):1418–1425. doi: 10.1016/S1473-3099(20)30239-5
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27:B3–12. doi: 10.1016/j.vaccine.2009.04.071
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–1253. doi: 10.4161/hv.24129
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327. doi: 10.1056/NEJMoa1900236
   PubMed Web of Science ®Google Scholar
• McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak—Oregon, 2015–2016. J Infect Dis. 2017;216(9):1130–1140. doi: 10.1093/infdis/jix446
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college—Rhode Island, 2015–2016. Clin Infect Dis. 2017;64(8):1115–1122. doi: 10.1093/cid/cix091
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Nolan T, Toneatto D, et al. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother. 2019;15(12):2940–2951. doi: 10.1080/21645515.2019.1627159
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Vesikari T, Senders SD, et al. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine MenB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine. 2021;39(32):4545–4554. doi: 10.1016/j.vaccine.2021.06.005
   PubMed Web of Science ®Google Scholar
• Serum Institute of India Pvt. Ltd. Multivalent meningococcal meningitis vaccine from Serum Institute of India achieves WHO prequalification [Internet]. [cited 2023 Jul 24]. Available from: https://www.seruminstitute.com/press_release_sii_120723.php
   Google Scholar
• Chen WH, Neuzil KM, Boyce CR, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect Dis. 2018;18(10):1088–1096. doi: 10.1016/S1473-3099(18)30400-6
   PubMed Web of Science ®Google Scholar
• Tapia MD, Sow SO, Naficy A, et al. Meningococcal serogroup ACWYX conjugate vaccine in Malian toddlers. N Engl J Med. 2021;384(22):2115–2123. doi: 10.1056/NEJMoa2013615
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. FDA approves Penbraya™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents [Internet]. [cited 2023 Nov 8]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-penbrayatm-first-and-only-vaccine-prevention
   Google Scholar
• ClinicalTrials.gov. Effectiveness of GlaxoSmithKline Biologicals S.A’s meningococcal group B and combined ABCWY vaccines in healthy adolescents and young adults [Internet]. [cited 2022 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04502693
   Google Scholar
• ClinicalTrials.gov. Immunogenicity and safety study of GSK’s MenABCWY vaccine in healthy adolescents and adults previously primed with MenACWY vaccine [Internet]. [cited 2022 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04707391
   Google Scholar
• Findlow H, Campbell H, Lucidarme J, et al. Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16. Euro Surveill. 2019;24(1):1700818. doi: 10.2807/1560-7917.ES.2019.24.1.1700818
   PubMedGoogle Scholar
• Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–366. doi: 10.1136/bmj.326.7385.365
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51(9):717–722. doi: 10.1099/0022-1317-51-9-717
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Laboratory confirmed cases of invasive meningococcal infection in England: annual report for 2021 to 2022 supplementary data tables [Internet]. [cited 2024 Jan 18]. Available from: https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-in-2021-to-2022
   Google Scholar
• Vesikari T, Peyrani P, Webber C, et al. Ten-year antibody persistence and booster response to MenACWY-TT vaccine after primary vaccination at 1-10 years of age. Hum Vaccin Immunother. 2020;16(6):1280–1291. doi: 10.1080/21645515.2020.1746110
   PubMed Web of Science ®Google Scholar
• Mbaeyi S, Pondo T, Blain A, et al. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 2020;174(9):843–851. doi: 10.1001/jamapediatrics.2020.1990
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Parikh SR, et al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6(2):96–105. doi: 10.1016/S2352-4642(21)00335-7
   PubMedGoogle Scholar
• Ohm M, Hahne SJM, van der Ende A, et al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2022;74(12):2173–2180. doi: 10.1093/cid/ciab791
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–357. doi: 10.1016/S0140-6736(83)90340-9
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126(5):514–521. doi: 10.1093/infdis/126.5.514
   PubMed Web of Science ®Google Scholar
• Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccin Immunother. 2015;11(1):5–13. doi: 10.4161/hv.34293
   PubMed Web of Science ®Google Scholar
• Martinon-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83(1):17–26. doi: 10.1016/j.jinf.2021.04.031
   PubMed Web of Science ®Google Scholar
• Marshall GS, Fergie J, Presa J, et al. Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review. Infect Dis Ther. 2022;11(3):937–951. doi: 10.1007/s40121-022-00609-9
   PubMed Web of Science ®Google Scholar
• Ramsay M Use of MLST in the epidemiology of meningococci [Internet]. [cited 2023 Jun 7]. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20140714074352/http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1194947392421
   Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725. doi: 10.1136/bmj.g5725
   PubMed Web of Science ®Google Scholar
• Leimkugel J, Racloz V, Jacintho da Silva L, et al. Global review of meningococcal disease. A shifting etiology. J Bacteriol Res. 2009;1:6–18.
   Google Scholar
• Chang Q, Tzeng YL, Stephens DS. Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol. 2012;4:237–245. doi: 10.2147/CLEP.S28410
   PubMedGoogle Scholar
• van Kessel F, van den Ende C, Oordt-Speets AM, et al. Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review. J Glob Health. 2019;9(1):010411. doi: 10.7189/jogh.09.010411
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326. doi: 10.1084/jem.129.6.1307
   PubMed Web of Science ®Google Scholar
• Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health. 2013;107(7):373–380. doi: 10.1179/2047773213Y.0000000119
   PubMed Web of Science ®Google Scholar
• Safadi MA, Bettinger JA, Maturana GM, et al. Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14(4):505–517. doi: 10.1586/14760584.2015.979799
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Blain AE, Wang X, et al. Current epidemiology and trends in meningococcal disease—United States, 1996–2015. Clin Infect Dis. 2018;66(8):1276–1281. doi: 10.1093/cid/cix993
   PubMed Web of Science ®Google Scholar
• Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis. 2017;17(8):867–872. doi: 10.1016/S1473-3099(17)30301-8
   PubMed Web of Science ®Google Scholar
• LaForce FM, Djingarey M, Viviani S, et al. Successful African introduction of a new group A meningococcal conjugate vaccine: future challenges and next steps. Hum Vaccin Immunother. 2018;14(5):1098–1102. doi: 10.1080/21645515.2017.1378841
   PubMed Web of Science ®Google Scholar
• Serra L, Knuf M, Martinon-Torres F, et al. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines. Hum Vaccin Immunother. 2021;17(7):2205–2215. doi: 10.1080/21645515.2020.1855952
   PubMed Web of Science ®Google Scholar
• Soumahoro L, Abitbol V, Vicic N, et al. Meningococcal disease outbreaks: a moving target and a case for routine preventative vaccination. Infect Dis Ther. 2021;10(4):1949–1988. doi: 10.1007/s40121-021-00499-3
   PubMed Web of Science ®Google Scholar
• Alderfer J, Isturiz RE, Srivastava A. Lessons from mass vaccination response to meningococcal B outbreaks at US universities. Postgrad Med. 2020;132(7):614–623. doi: 10.1080/00325481.2020.1766265
   PubMed Web of Science ®Google Scholar
• Caron F, du Chatelet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455–463. doi: 10.1016/S1473-3099(11)70027-5
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Vaccine Scheduler. Meningococcal Disease: Recommended Vaccinations [Internet]. [cited 2024 Jan 24]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1
   Google Scholar
• Wang B, Giles L, Andraweera P, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis. 2022;22(7):1011–1020. doi: 10.1016/S1473-3099(21)00754-4
   PubMed Web of Science ®Google Scholar
• Castilla J, Garcia Cenoz M, Abad R, et al. Effectiveness of a meningococcal group B vaccine (4CMenB) in children. N Engl J Med. 2023;388(5):427–438. doi: 10.1056/NEJMoa2206433
   PubMed Web of Science ®Google Scholar
• Tin Tin Htar M, Jackson S, Balmer P, et al. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health. 2020;20:1890. doi: 10.1186/s12889-020-09946-1
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193. doi: 10.1542/peds.2016-2193
   PubMed Web of Science ®Google Scholar
• Koliou M, Kasapi D, Mazeri S, et al. Epidemiology of invasive meningococcal disease in Cyprus 2004 to 2018. Euro Surveill. 2020;25(30):1900534. doi: 10.2807/1560-7917.ES.2020.25.30.1900534
   PubMedGoogle Scholar
• Fernandez K, Lingani C, Aderinola OM, et al. Meningococcal meningitis outbreaks in the African meningitis belt after meningococcal serogroup A conjugate vaccine introduction, 2011–2017. J Infect Dis. 2019;220(suppl 4):S225–S232. doi: 10.1093/infdis/jiz355
   PubMedGoogle Scholar
• US Centers for Disease Control and Prevention. Meningococcal disease outbreak among gay, bisexual men in Florida, 2021–23 [Internet]. [cited 2024 Jan 30]. Available from: https://www.cdc.gov/meningococcal/outbreaks/FL2022.html
   Google Scholar
• Ladhani SN, Lucidarme J, Parikh SR, et al. Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis. Lancet. 2020;395(10240):1865–1877. doi: 10.1016/S0140-6736(20)30913-2
   PubMed Web of Science ®Google Scholar
• Badur S, Al Dabbagh MA, Shibl AM, et al. The epidemiology of invasive meningococcal disease in the Kingdom of Saudi Arabia: a narrative review with updated analysis. Infect Dis Ther. 2021;10(4):2035–2049. doi: 10.1007/s40121-021-00467-x
   PubMed Web of Science ®Google Scholar
• Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W meningococcal disease (1970–2015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 2016;34(13):1515–1523. doi: 10.1016/j.vaccine.2016.02.014
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71(5):544–552. doi: 10.1016/j.jinf.2015.07.007
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Scott KJ, Ure R, et al. An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016;21(45):30395. doi: 10.2807/1560-7917.ES.2016.21.45.30395
   PubMedGoogle Scholar
• Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–585. doi: 10.1093/cid/ciu881
   PubMed Web of Science ®Google Scholar
• Booy R, Gentile A, Nissen M, et al. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15(2):470–480. doi: 10.1080/21645515.2018.1532248
   PubMed Web of Science ®Google Scholar
• Villena R, Valenzuela MT, Bastias M, et al. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction. Vaccine. 2022;40(4):666–672. doi: 10.1016/j.vaccine.2021.11.075
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report. 2019 [Internet]. [cited 2022 Dec 27]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2019.pdf
   Google Scholar
• Zumla A, Memish ZA. Risk of antibiotic resistant meningococcal infections in Hajj pilgrims. BMJ. 2019;366:l5260. doi: 10.1136/bmj.l5260
   PubMedGoogle Scholar
• Micoli F, Bagnoli F, Rappuoli R, et al. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol. 2021;19(5):287–302. doi: 10.1038/s41579-020-00506-3
   PubMed Web of Science ®Google Scholar
• Brooks A, Lucidarme J, Campbell H, et al. Detection of the United States Neisseria meningitidis urethritis clade in the United Kingdom, August and December 2019 – emergence of multiple antibiotic resistance calls for vigilance. Euro Surveill. 2020;25(15):2000375. doi: 10.2807/1560-7917.ES.2020.25.15.2000375
   PubMedGoogle Scholar
• Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3(6):e360–e370. doi: 10.1016/S2589-7500(21)00077-7
   PubMedGoogle Scholar
• Middeldorp M, van Lier A, van der Maas N, et al. Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020. Vaccine. 2021;39(7):1039–1043. doi: 10.1016/j.vaccine.2020.12.080
   PubMed Web of Science ®Google Scholar
• Taha S, Hong E, Denizon M, et al. The rapid rebound of invasive meningococcal disease in France at the end of 2022. J Infect Public Health. 2023;16(12):1954–1960. doi: 10.1016/j.jiph.2023.10.001
   PubMed Web of Science ®Google Scholar
• Clark SA, Campbell H, Ribeiro S, et al. Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England. J Infect. 2023;87(5):385–391. doi: 10.1016/j.jinf.2023.09.002
   PubMed Web of Science ®Google Scholar
• Virginia Department of Health. Virginia Department of Health Declares Statewide Outbreak of Meningococcal Disease [Internet]. [cited 2024 Jan 18]. Available from: https://www.vdh.virginia.gov/clinicians/virginia-department-of-health-declares-statewide-outbreak-of-meningococcal-disease/
   Google Scholar
• GlaxoSmithKline. Half of parents surveyed either cancelled or delayed their child’s scheduled meningitis vaccination during the COVID-19 pandemic – GSK survey shows [Internet]. [cited 2022 May 17]. Available from: https://www.gsk.com/en-gb/media/press-releases/half-of-parents-surveyed-either-cancelled-or-delayed-their-child-s-scheduled-meningitis-vaccination-during-the-covid-19-pandemic-gsk-survey-shows-1/
   Google Scholar
• Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol. 2004;42(11):5146–5153. doi: 10.1128/JCM.42.11.5146-5153.2004
   PubMed Web of Science ®Google Scholar
• Peterson ME, Li Y, Shanks H, et al. Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis. BMJ Open. 2019;9(4):e024343. doi: 10.1136/bmjopen-2018-024343
   PubMed Web of Science ®Google Scholar
• Cooper LV, Kristiansen PA, Christensen H, et al. Meningococcal carriage by age in the African meningitis belt: a systematic review and meta-analysis. Epidemiol Infect. 2019;147:e228. doi: 10.1017/S0950268819001134
   PubMed Web of Science ®Google Scholar
• Australian Government Department of Health and Aged Care. National Immunisation Program Schedule [Internet]. [cited 2024 Jan 25]. Available from: https://www.health.gov.au/sites/default/files/2023-11/national-immunisation-program-schedule.pdf
   Google Scholar
• Ministério da Saúde do Brasil. Calendário de Vacinação [Internet]. [cited 2023 Nov 6]. Available from: https://www.gov.br/saude/pt-br/vacinacao/calendario
   Google Scholar
• Government of Canada. Meningococcal Vaccines: Canadian Immunization Guide [Internet]. [cited 2023 Nov 6]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html
   Google Scholar
• Ministerio de Salud (Gobierno de Chile). Calendario de Vacunación 2023 [Internet]. [cited 2023 Nov 6]. Available from: https://saludresponde.minsal.cl/wp-content/uploads/2023/03/CALENDARIO-VACUNACION-2023.png
   Google Scholar
• Ministerio de Salud (Republica Argentina). Calendario Nacional de Vacunación 2022 [Internet]. [cited 2023 Nov 6]. Available from: https://bancos.salud.gob.ar/recurso/calendario-nacional-de-vacunacion-2022
   Google Scholar
• UK National Health Service. Vaccination: Meningitis [Internet]. [cited 2024 Jan 24]. Available from: https://www.nhs.uk/conditions/meningitis/vaccination/
   Google Scholar
• US Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger [Internet]. [cited 2023 Jul 26]. Available from: https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
   Google Scholar
• New Zealand Ministry of Health. Immunisation handbook 2020: 13. Meningococcal disease [Internet]. [cited 2023 Nov 6]. Available from: https://www.health.govt.nz/our-work/immunisation-handbook-2020/13-meningococcal-disease#12-5
   Google Scholar
• US Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older [Internet]. [cited 2023 Feb 13]. Available from: https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf
   Google Scholar
• State of Israel Ministry of Health. Vaccines for babies and children [Internet]. [cited 2023 Feb 13]. Available from: https://www.health.gov.il/English/Topics/Pregnancy/Vaccination_of_infants/Pages/default.aspx
   Google Scholar
• Blanchard-Rohner G. Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: a comprehensive review and practical guide. Front Immunol. 2021;12:711637. doi: 10.3389/fimmu.2021.711637
   PubMed Web of Science ®Google Scholar
• Czumbel I, Quinten C, Lopalco P, et al. Management and control of communicable diseases in schools and other child care settings: systematic review on the incubation period and period of infectiousness. BMC Infect Dis. 2018;18(1):199. doi: 10.1186/s12879-018-3095-8
   PubMed Web of Science ®Google Scholar
• Tsang RSW. A narrative review of the molecular epidemiology and laboratory surveillance of vaccine preventable bacterial meningitis agents: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae and Streptococcus agalactiae. Microorganisms. 2021;9:449. doi: 10.3390/microorganisms9020449
   PubMed Web of Science ®Google Scholar